Cellectar is a biopharmaceutical company developing targeted cancer therapeutics using its proprietary phospholipid ether drug conjugate (PDC) platform, which delivers therapeutic payloads such as radioisotopes directly to tumor cells while minimizing harm to healthy tissue. The company's pipeline focuses on radioconjugate PDC programs designed to address unmet needs in orphan cancer indications including hematologic malignancies like Waldenstrom macroglobulinemia and multiple myeloma as well as solid tumors such as pancreatic and breast cancer. Currently in clinical development stages, the company generates no product revenue but is advancing multiple lead candidates through regulatory pathways, with plans to eventually commercialize approved therapies and generate revenue through product sales and potential collaborations.